Xeris Biopharma Holdings, Inc. (XERS): auditor change — Xeris Biopharma replaces KPMG with Ernst & Young as independent auditor

Xeris Biopharma Holdings, Inc.

Audit committee dismissed KPMG as independent registered public accounting firm on March 13, 2023.
KPMG's reports for FY2022 and FY2021 had no adverse opinion except for a lease accounting change.
No disagreements or reportable events occurred during the audit periods or interim period through March 13, 2023.
Ernst & Young engaged as new independent auditor for the fiscal year ending December 31, 2023.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Xeris Biopharma Holdings, Inc. engaged Ernst & Young LLP as its auditor.

Action: engagement
Auditor: Ernst & Young LLP

Exact text from the filing

On March 13, 2023, the Audit Committee of the Board approved the engagement of Ernst & Young LLP ("E&Y") as its new independent registered public accounting firm to audit the Company's financial statements for the fiscal year ending December 31, 2023.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Xeris Biopharma Holdings, Inc. dismissed KPMG LLP as its auditor.

Action: dismissal
Auditor: KPMG LLP
Successor: Ernst & Young LLP

Exact text from the filing

On March 13, 2023, the audit committee (the "Audit Committee") of the board of directors (the "Board") of Xeris Biopharma Holdings, Inc. and subsidiaries (the "Company") approved the dismissal of KPMG LLP ("KPMG") as the Company's independent registered public accounting firm and KPMG was dismissed.

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.